Ingredient or product comparison
GHK-Cu TB-500 Protocol Skin Healing Research: Evidence Comparison
Full-thickness excision (rat) 3mg daily days 4–21 7.5mg 2×/week days 1–14 42% faster vs monotherapy +68% type I collagen +3.1-fold capillary density Strongest evidence for sequential dosing. TB-500 early, GHK-Cu proliferative phase Burn wound (porcine) 5mg dai
This source-based comparison does not add ratings or recommend a winner.
- Full-thickness excision (rat)
- 3mg daily days 4–21
- 7.5mg 2×/week days 1–14
- 42% faster vs monotherapy
- +68% type I collagen
- +3.1-fold capillary density
- Strongest evidence for sequential dosing. TB-500 early, GHK-Cu proliferative phase
- Burn wound (porcine)
- 5mg daily days 1–28
- 10mg 2×/week days 1–21
- 31% faster vs control
- +54% total collagen
- +2.4-fold VEGF expression
- High TB-500 dose justified in severe thermal injury but GHK-Cu likely wasted in necrotic phase
- Diabetic ulcer model (mouse)
- 2mg daily continuous
- 5mg 3×/week continuous
- 29% faster vs untreated
- +41% type III collagen
- +1.8-fold microvascular density
- Chronic wound context changes timing. Continuous low-dose outperforms bolus in impaired healing
- Surgical incision (human biopsy)
- Topical 0.1% gel 2×/day
- Not evaluated
- 18% faster vs placebo gel
- +23% dermal thickness
- Not measured
- Topical GHK-Cu shows modest effect. Parenteral administration likely superior for deep wounds